Clinical trials: Prostate Cancer, not yet recruiting
High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
This study was to evaluate the safety and efficacy of dalcilide tablets in combination with AA-P in the treatment of subjects with high tumor burden mHSPC and to determine the second stage starting dose and progression-free…
- Trial name
- NCT06099990
- Testing
- dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets
- Volunteers
- 660 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Prostate Cancer
A Study of QLS2401 Injection in Participants With Advanced Prostate Cancer
This study is an open-label, dose-escalation and efficacy-expansion Phase I clinical trial designed to evaluate the safety, tolerability, pharmacokinetic (PK) profile, immunogenicity, and preliminary antitumor activity of QLS2401…
- Trial name
- NCT07869888
- Testing
- QLS2401
- Volunteers
- 252 people
- Sponsor
- Shanghai Qilu Pharmaceutical Research and Development Center LTD
Prostatic Neoplasms
A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer
The purpose of this study is to evaluate how well JNJ-101556143 plus Best Supportive Care (BSC) improves overall survival (the length of time a participant remains alive) compared with placebo plus BSC in participants with…
- Trial name
- NCT07906717
- Testing
- JNJ-101556143, Best Supportive Care
- Volunteers
- 400 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer Metastatic Castration-Resistant
A Study of KMV002 in Patients With mAPMR Prostate Cancer
This is a first-in-human (FIH) open-label, multicenter, dose-escalation and dose-expansion Phase I study of KMV002 in metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer patients.
- Trial name
- NCT07866300
- Testing
- KMV002
- Where
- 2 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Chimivac INC
Prostate Cancer
Water Vapor Ablation for Grade Group 3 Prostate Cancer
The goal of this study is to evaluate the safety and effectiveness of the Vanquish Water Vapor Ablation System ("Vanquish") in participants with Grade Group 3 (GG3) intermediate-risk prostate cancer.
- Trial name
- VAPOR 3 (NCT07652164)
- Testing
- Water Vapor Ablation
- Volunteers
- 120 people
- Sponsor
- Francis Medical Inc.
Prostate Cancer
Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The primary objective of this study is to compare overall survival (OS) in patients with progressive PSMA-positive mCRPC who receive 177Lu-NYM032 in addition to best supportive/best standard of care versus patients treated with…
- Trial name
- NCT07795268
- Testing
- 177Lu-NYM032 injection, Best supportive/best standard of care
- Volunteers
- 600 people
- Sponsor
- Norroy Bioscience Co., LTD
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）
This study is to evaluate the safety, and preliminary antitumor activity of TY-302 combined with Abiraterone tablets in patients with metastatic castration-resistant prostate cancer (mCRPC) that have failed novel endocrine therapy
- Trial name
- NCT07104617
- Testing
- TY-302, Abiraptor
- Where
- China
- Volunteers
- 48 people
- Sponsor
- TYK Medicines, Inc
HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies
The goal of this Phase 1/2a interventional study is to evaluate the safety and tolerability of CRG-150 in relapsed/refractory HR+HER2- breast cancer, Triple Negative Breast Cancer (TNBC) and prostate cancer.
- Conditions
- HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Prostate Cancer
- Trial name
- NCT07730125
- Testing
- CRG-150
- Volunteers
- 67 people
- Sponsor
- CoRegen, Inc.
Metastatic Castration-resistant Prostate Cancer, MCRPC
A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer
A total of 75 participants will be enrolled in the study, with 25 participants allocated per intervention group. In Group 1, participant will take 50 mg cabazitaxel every week for 6 cycles (3 doses per cycle), 10 mg prednisone…
- Trial name
- NCT06890832
- Testing
- 50 mg cabazitaxel, 100 mg cabazitaxel, 200 mg cabazitaxel
- Volunteers
- 75 people
- Sponsor
- Jina Pharmaceuticals Inc.
Solid Tumor Cancer, Castration Resistant Metastatic Prostate Cancer
ITR-251 in Patients With Advanced Solid Tumors
This is an open-label, Phase I/Ib trial including an initial dose-escalation phase in patients with advanced solid tumors and a dose-expansion phase at recommended phase 2 dose (RP2D) in combination with Androgen Receptor Pathway…
- Trial name
- STRIVE-251 (NCT07870096)
- Testing
- ITR-251, ITR-251 at RP2D, ARPI therapy
- Where
- Spain
- Volunteers
- 46 people
- Sponsor
- ITERIA BIOPHARMA, S.L.
Prostate Cancer, Recurrent Prostate Cancer
Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Recurrent Prostate Cancer
This is a multi-center clinical study enrolling up to 12 participants . The primary objective of the study is to evaluate the safety of Alpha DaRT for the treatment of locally recurrent prostate cancer .
- Conditions
- Prostate Cancer, Recurrent Prostate Cancer, Locally Recurrent Prostate Cancer
- Trial name
- NCT07290998
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Volunteers
- 12 people
- Sponsor
- Alpha Tau Medical LTD.
Neuroendocrine Prostate Cancer
Study of ZG006 in Participants With Neuroendocrine Prostate Cancer
This is a multicenter, open-label Phase II study, aimed at exploring the preliminary efficacy and safety of ZG006 in patients with advanced metastatic NEPC who have previously failed standard treatment.
- Trial name
- NCT07024277
- Testing
- ZG006
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Recurrent Prostate Cancer
Determining Patterns In Trial Experiences of Recurrent Prostate Cancer Patients
Clinical studies, with a dedicated focus on recurrent prostate cancer, play a pivotal role in evaluating the safety and effectiveness of novel treatments for this condition.
- Trial name
- NCT06070272
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Localised Prostate Cancer
Microwave Intervention Under Local Anesthesia
This study aims to evaluate the feasibility of performing a focal Targeted Microwave Ablation (TMA) procedure using Koelis TMA® under local anesthesia in patient with localized prostate cancer.
- Trial name
- MILA (NCT07412275)
- Testing
- Local Anesthesia (lidocaine hydrochloride)
- Where
- 2 sites in Belgium, France
- Volunteers
- 20 people
- Sponsor
- Koelis
Prostatic Neoplasms
Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer
This study is designed to determine if experimental treatment with QLH12016 in combination with novel hormonal agent (NHA) is safe, tolerable, and has anti-cancer activity in patients with advanced prostate cancer.
- Trial name
- NCT07104110
- Testing
- QLH12016, abiraterone acetate, enzalutamide
- Volunteers
- 50 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Prostate Cancer
QLC5508 in Participants With Metastatic Prostate Cancer
This is a randomized, open-label, active-controlled, multicenter Phase III trial evaluating QLC5508 versus docetaxel in participants with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after prior…
- Trial name
- NCT07632690
- Testing
- QLC5508, Docetaxel
- Volunteers
- 700 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate
RYZ711 Diagnostic Platform Study
This is a Phase 1/2 multicenter, multi-cohort imaging study to evaluate the safety, tolerability, and diagnostic performance of RYZ711 positron emission tomography/computed tomography (PET/CT) in men with histologically confirmed…
- Conditions
- Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate, Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Trial name
- NCT07862582
- Testing
- RYZ711, PSMA PET/CT
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- RayzeBio, Inc.
Castration-resistant Prostate Cancer
A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer
This study will first conduct a phase II clinical study, and on the basis of the phase II clinical study, subsequent clinical research will be carried out.
- Trial name
- NCT07641855
- Testing
- BL-B01D1, Abiraterone, Olaparib
- Where
- 2 sites in China
- Volunteers
- 180 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Metastatic Castration Resistant Prostate Cancer
Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC)
The goal of this clinical trial is to test GT-220F in patients with metastatic castration resistant prostate cancer and learn about the best dose required for further study.
- Trial name
- NCT06866795
- Testing
- GT-220F capsule
- Volunteers
- 42 people
- Sponsor
- Geode Therapeutics Inc.
Prostate Cancer
dMD-002 Pilot Study in Patients With Cavernous Nerve Injury Following Radical Prostatectomy
The purpose of this study is to conduct a US Pilot study of dMD-002 as a peripheral nerve repair sheet in patients with cavernous nerve injury following radical prostatectomy.
- Trial name
- NCT07564102
- Testing
- dMD-002, Control
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mochida Medical USA, Inc.